Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06050304
Other study ID # 2022-A02072-41
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 2023
Est. completion date September 2024

Study information

Verified date August 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Florence Vorspan, MD, PhD
Phone 01 40 05 44 17
Email Florence.vorspan@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research focuses on behavioral sensitization (BS) a specific behavioural disturbance in crack-cocaine addiction. The primary objective is to observe whether BS can be demonstrated in an ecological setting in crack dependent users by continuous actimetry for 3 weeks. It is planned to include 20 persons with a current crack-cocaine addiction with a preferential use of rapid administration route (intravenous or smoke), in a care institution: Fernand Widal Hospital. In the proposed research, the investigators will assess the movements of crack-cocaine dependent users in relation to consumption. They will have to wear continuously for 3 weeks an actimeter. They will also have 3 blood tests trying to identify biomarkers of BS.


Description:

Paris region and the French west indies face a specific epidemic of crack-cocaine use, mostly by socially deprived subjects, highly visible in open drug scenes, with little access to the care system. Patients who suffer from crack-cocaine dependence experiment a high rate of medical and a high mortality rate, because this type of cocaine is a short-acting form, used through rapid route of administration (usually smoked or injected). Nevertheless, despite important uncovered medical needs, they are not often included in clinical trials and there is to date no pharmacological treatment for this severe condition. The investigators identified behavioral disturbances as a key problem in crack-cocaine dependence, as it is the second cause for emergency visits for those patients and a reason to be excluded from addiction care facilities. Based on preliminary results already gathered by our group, the investigators suggest that behavioral sensitization (BS), an increase of motor response to cocaine after repetitive intermittent use, could be assessed in Humans. Our goal is therefore to include 20 persons (10 males - 10 females) with a current cocaine use disorder,specifically crack users, with preferential use of rapid administration route (intravenous or smoke), in a care institution: the Fernand Widal Hospital (Assistance Publique - Hôpitaux de Paris). The investigators will assess the movements of crack-cocaine dependent users in relation to consumption. They will have to wear continuously for 3 weeks an actimeter, in the form of a small watch, which collects the level of motor activity throughout the day and night. They will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. The investigators want to know if certain uses lead to more behavioral problems (especially after periods of cessation). They will also have 3 blood tests: the investigators want to know if blood proteins, genetic markers passed on by paricipants parents or the expression of proteins in particular situations, could predict this increase in motor effects for small doses of crack-cocaine. The investigators also want to better understand the needs of crack-cocaine dependent patients towards treatments and their expectations for recovery, by conducting a qualitative study where patients will participate in the definition of treatment aims to increase the efficiency of care With the project CRACK-TARGET 1 : DETA, the investigators aim at demonstrating the existence of BS in patients with crack dependent subjects. Furthermore, the investigators aim at developing specific, repeatable, easy to access measure of BS using questionnaires and objective actigraphy biomarkers to be used as surrogate endpoints in clinical trials.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - > 18 years - Have a current crack-cocaine use disorder defined as Severe Intensity Use Disorder (6 or more DSM5 criteria), AND preferential use of rapid administration route (intravenous or smoked) - Self-identified male or female (n=10 males, n=10 females) - Negative pregnancy test for females and use of effective contraception - Be affiliated with a social security plan (or PUMA or CSS or AME) - Sign an informed consent and commit to a 3-week follow-up in the study - Have a weight greater than 40 kg Exclusion Criteria: - • Patient with a psychiatric disorder or symptoms that are not currently stabilized - Patient who is a minor or under protective supervision (curatorship or guardianship) - Patient in care at the request of a judicial authority (therapeutic injunction, classification with orientation) - Pregnant or breastfeeding women - Patients who do not speak French or English sufficiently - Patients weighing less than 40 kg

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter
In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).
Biological:
3 blood tests
We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations

Locations

Country Name City State
France Hôpital Fernand Widal Paris

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other A/G % in rs7568970 polymorphism of the LRP1B gene in patients with observed versus without observed BS Fold change of the methylation status of the LRP1B gene in patients with observed versus without observed BS 3 weeks
Primary Reduction in sleep duration(hours/minutes) on crack-cocaine use days following a break of at least 2 days compared to crack-cocaine use days without any break (means over the 3 weeks period) Reduction in sleep duration(hours/minutes) on crack-cocaine use days following a break of at least 2 days compared to crack-cocaine use days without any break (means over the 3 weeks period) 3 Weeks
Secondary Earlier onset of M10(the time of day when the 10 hours of peak motor activity begins, a reflection of the "motor wake-up time). The time of day when the 10 hours of peak motor activity begins, a reflection of the "motor wake-up time") (hours/minutes) during crack-cocaine use days following a 2 days break compared to crack-cocaine use days without any break (comparison of mean M10 time) 3 Weeks
Secondary Shorter relative amplitude of motor activity (the relative difference between M10) Average activity level during the most active 10-hour period) and L5 (average activity level during the least active 5-hour period) (hours/minutes) during crack-cocaine use days following a 2 days break compared to crack-cocaine use days without any break (comparison of mean relative amplitudes over 3 weeks 3 Weeks
Secondary Self-defined patients' expectations toward treatment measured in qualitative interviews Expectations toward treatment measured in qualitative interviews 3 Weeks
Secondary Higher scores assessed with questionnaires that approximate BS Higher scores assessed with questionnaires that approximate BS 3 weeks
Secondary WURS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS WURS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS 3 weeks
Secondary ASRS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS ASRS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS 3 weeks
Secondary SAPS-CIP in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS SAPS-CIP in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS 3 weeks
Secondary YMRS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS YMRS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS 3 weeks
Secondary UPPS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS UPPS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS 3 weeks
Secondary PDI in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS PDI in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS 3 weeks
Secondary PANSS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS PANSS in patients presenting with at least 1 of the 3 previously defition of BS on actimetric measures compared to patients without BS 3 weeks
See also
  Status Clinical Trial Phase
Completed NCT03538548 - Treatment Outcome in CBT for Cocaine Use N/A
Recruiting NCT04994821 - tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study Phase 2
Completed NCT02239913 - Topiramate-Phentermine Combinations for Cocaine Dependence Phase 1
Completed NCT02233647 - Phendimetrazine and Cocaine Early Phase 1
Not yet recruiting NCT05974202 - rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder Phase 2
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT03224546 - Cocaine Use Reduction and Health N/A
Recruiting NCT03656653 - Imagery-based Coping for Cocaine Use Disorder N/A
Completed NCT03348384 - [11C]NOP-1A and Cocaine Use Disorders Early Phase 1
Recruiting NCT05019430 - Cocaine and Zolmitriptan Early Phase 1
Recruiting NCT03344419 - Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders Phase 3
Recruiting NCT05507814 - Temporal Window and Episodic Future Thinking in CUD N/A
Active, not recruiting NCT03799341 - Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project N/A
Completed NCT02785406 - Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use Phase 2
Completed NCT02798627 - Trial Of NS2359 For The Treatment of Cocaine Dependence Phase 2
Completed NCT02444208 - A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use N/A
Recruiting NCT05902819 - Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories N/A
Recruiting NCT05833529 - Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder N/A
Recruiting NCT05521854 - Contingency Management for Drug Use: Does Age Matter? N/A
Completed NCT05557149 - Virtual Reality Exposure and Respiratory Relaxation-Based Coping With Cocaine Craving in Cocaine Users N/A